OKYO Pharma logo

OKYO - OKYO Pharma News Story

11.25p -0.3  -2.2%

Last Trade - 4:28pm

Sector
Healthcare
Size
Small Cap
Market Cap £73.2m
Enterprise Value £73.0m
Revenue £n/a
Position in Universe 1053rd / 1803

OKYO Pharma Limited - Notice of AGM

Wed 9th September, 2020 7:00am
For best results when printing this announcement, please click on link below:
http://pdf.reuters.com/htmlnews/htmlnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20200909:nRSI4020Ya

RNS Number : 4020Y  OKYO Pharma Limited  09 September 2020

OKYO Pharma Limited

("OKYO" or the "Company")

Notice of Annual General Meeting

OKYO Pharma Limited (LSE: OKYO), the life sciences and biotechnology company
focused on the discovery and development of novel molecules to treat
inflammatory dry eye diseases and chronic pain, is pleased to announce that it
will hold its annual general meeting ("AGM") on 25 September 2020 at 10:00
a.m.

The Notice of AGM, together with a proxy form and the Annual Report and
Accounts for the year ended 31 March 2020, will be posted to shareholders
today. The Notice of AGM will shortly also be available on the Company's
website: www.okyopharma.com (http://www.okyopharma.com)

Please note that arrangements for the AGM this year are different from the
usual public company in-person format. As we expect significant restrictions
on personal movement to still be in place due to Covid-19, we are utilizing
the provisions in our recently adopted articles of association, which allow
for the holding of the meeting virtually, on an electronic platform.
Accordingly, this year's AGM will be an electronic meeting only. All voting at
the resolutions at the AGM will be conducted on a poll (a requirement of our
recently adopted articles of association) which means that you should submit
your proxy (by post or, preferably, online voting) as soon as possible. We ask
that, where possible, questions which shareholders wish to raise be submitted
to info@okyopharma.com in advance.

The platform that we will be using will allow shareholders the option to
submit a separate poll card at the electronic meeting but, to ease
administration, we request that proxies be lodged in advance wherever
possible.

Full details of the operation and arrangements for the AGM are set out in the
Notice of AGM.

About OKYO Pharma Limited

OKYO Pharma Limited (LSE: OKYO) is a life sciences and biotechnology company
admitted to listing on the standard segment of the Official List of the UK
Financial Conduct Authority and to trading on the Main Market for listed
securities of the London Stock Exchange plc. OKYO is focusing on the discovery
and development of novel molecules to treat inflammatory dry eye diseases and
chronic pain.

Enquiries:

OKYO Pharma Limited          Willy
Simon                 +44 (0)20 7495 2379

Optiva Securities Limited        Robert Emmet           + 44
(0)20 3981 4173

RedChip Companies Inc.       Dave Gentry               +1
407-491-4498

                                                                                   dave@redchip.com

For further information, please visit the Company's website at
www.okyopharma.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOAFFFVFARITIII
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.